Pharmaceutical companies Moderna and Merck announced Tuesday that a new melanoma vaccine tested at sites including Pittsburgh showed promising results.
The vaccine uses messenger RNA, or mRNA, technology, like Moderna’s COVID-19 vaccine, and reduced the likelihood of melanoma recurrence by 44%. The results represent what scientists are calling a key moment in cancer therapy.
Dr. Jason Luke, associate professor of medicine in the Division of Hematology and Oncology at the University of Pittsburgh, the director of the Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center and a melanoma physician, said this was “potentially a watershed moment of the use of mRNA technology in cancer.”
UPMC Hillman Cancer Center participated in the Phase 2 clinical trial that treated 157 patients, who had either stage III or IV melanoma, meaning the skin cancer had spread to their lymph nodes or other organs. Merck Research Laboratories and Moderna worked together to create the mRNA portion of the vaccine that in the trial was combined with Keytruda, a cancer immunotherapy treatment. This combined vaccine worked better to reduce cancer recurrence than Keytruda alone.
Paul Burton, Moderna’s chief medical officer, said that the combination “has the capacity to be a new paradigm in the treatment of cancer,” Reuters reported.
Nearly 100,000 Americans are given melanoma diagnoses each year and around 8,000 die from it, according to the American Cancer Society. And while it accounts for only 1% of skin cancers, it is responsible for a majority of skin cancer deaths. Dr. Luke said melanoma is one of the few cancers that is increasing in incidence each year. While melanoma caught at stage I is easily treatable and has a high survival rate, once it reaches more advanced stages the five-year survival rate drops dramatically to 25% to 30%.
To create a personalized vaccine to match each patient’s immune system, scientists sequenced the DNA from patients’ surgically removed melanoma. They compared this cancerous DNA to a patient’s noncancerous DNA (say, from a mouth swab) to identify mutations in it. They then used computer algorithms to detect which mutated proteins each patient’s immune system would recognize.
A unique mRNA sequence was then synthesized, which codes for the mutated proteins and trains each patient’s immune system to recognize the similarly mutated cancer cells. Similar to how the mRNA COVID-19 vaccine codes only for the spike protein, which helps the body fight a COVID-19 infection, this vaccine acts like a training session for a cancer patient’s immune system.
Dr. Luke said the results from this trial illustrate the first “clinically meaningful difference” for cancer patients in what is called neoantigen technology. With this success, scientists are planning to initiate a Phase 3 global randomized clinical trial of approximately 1,500 patients to begin in 2023, also including UPMC.
If a Phase 3 trial shows a new drug is more effective or safer than the current treatment, it can be submitted to the Food and Drug Administration for approval.
There’s plenty of evidence in the medical literature that mRNA technology is safe, Dr. Luke said. It does not alter DNA directly; it only tells the body to code for certain proteins that are promptly destroyed by the immune system. And he said there’s little risk for a heightened immune response — other neoantigen studies have not seen that complication. Keytruda alone does cause some side effects, such as fatigue, pain, diarrhea and a fever.
The success of this study points to new directions for cancer therapy and represents possibilities for cancer treatment for patients being treated at UPMC Hillman Cancer Center, Dr. Luke said.
“Though it sort of sounds like science fiction, this is where standard medicine is going,” he said.
Hanna Webster: hwebster@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.